[CAS NO. 2169919-21-3] Revumenib
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [2169919-21-3]
Catalog
SLK-S8996
Brand
Selleck
CAS
2169919-21-3
DESCRIPTION [2169919-21-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 630.82 |
| Molecular Formula | C32H47FN6O4S |
| SMILES | - |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5852 mL | 7.9262 mL | 15.8524 mL |
| 5 mM | 0.3170 mL | 1.5852 mL | 3.1705 mL |
| 10 mM | 0.1585 mL | 0.7926 mL | 1.5852 mL |
| 50 mM | - | - | - |
Description
Revumenib(SNDX-5613) is a potent and selective inhibitor of with a Ki of 0.15 nM. SNDX-5613 shows anti-proliferative activity against multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8) with IC50 values ranging from 10-20 nM.
Targets
| menin-MLL binding [1] |
| 0.15 nM(Ki) |
In vitro
SNDX-5613 has anti-proliferative activity against multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8). SNDX-5613 doesn't inhibit growth of HL-60, a promyelocytic leukemia cell line lacking an MLL rearrangement , indicating selective activity towards leukemic cells lines that harbor MLL-rearranged (MLLr) fusion proteins.[1]
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.